| Name | Title | Contact Details |
|---|
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.
miR’s Disease Management Platform™ gives providers and patients first-time access to actionable health data, illuminating a clear path to cancer management.
Novartis Animal Health, US is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.